|
|
|
| The Next Generation Of mRNA Products: Implications For Quality Control | Driven by influential regulatory, business, and scientific forces, mRNA has the potential to revolutionize patient treatment over the next decade. Technological advances that will support these patients include novel RNAs, tissue-targeting lipid nanoparticles, non-lipid nanoparticle delivery vehicles, non-needle administration systems, and decentralized manufacturing models. Nevertheless, these solutions will require novel analytical methods to characterize critical quality attributes and confirm products’ safety and efficacy. Learn more. |
|
|
|
|
By S. Acharya, U.S. Pharmacopeia, and K. Yamout, consultant | The United States Pharmacopeia held a forum in February to exchange ideas about analytical methodologies and release testing for mRNA vaccines and therapeutics. Here's a recap of the event. |
|
|
|
A conversation with Roger Nosal, NGT BioPharma Consultants | An inaugural survey revealed that a lack of harmonized regulations slows the advancement of alternative drug modalities and advanced manufacturing technology. |
|
|
|
This Advancing RNA panel of experts shares several important questions those striving to make RNA therapeutics will find themselves confronting when collaborating with regulators. |
|
|
|
|
|
|
|
| Introduction To mRNA Manufacturing | Article | Cytiva | The SARS-CoV-2 virus has changed the course of scientific research around mRNA. Learn about mRNA manufacturing, the structure of an mRNA molecule, RNase-free considerations, and more. |
|
|
|
|
|
.png){kind=logo}
